Table 2 Clinical responses to treatment
Response to treatment | Group I (N = 47) 2002–2005 | Group II (N = 22) 2005–2007 | P value | ||
|---|---|---|---|---|---|
| Â | N | % | N | % | Â |
Initial HAART regimen | Â | Â | Â | Â | Â |
• Nelfinavir-containing regimen | 47 | 100 |  |  |  |
• Efavirenz-containing regimen |  |  | 22 | 100 |  |
Discontinued HAART within one year of initiation | Â | Â | Â | Â | Â |
Laboratory ASEs* (Grade 3 or 4) | Â | Â | Â | Â | Â |
• Grade 3 | 4 | 8.5 | 1 | 4.5 | 0.9 |
• Grade 4 | 0 | 0 | 1 | 4.5 | 0.319 |
New opportunistic infections (overall) | 8 | 17.0 | 2 | 9.1 | 0.484 |
• CNS toxoplasmosis | 6 | 12.8 | 0 | 0 |  |
• CMV retinitis | 1 | 2.1 | 0 | 0 |  |
• PCP pneumonia | 0 | 0 | 2 | 9.1 |  |
• Cryptococcal infection | 1 | 2.1 | 0 | 0 |  |
TB outcomes | Â | Â | Â | Â | Â |
• Cure | 22 | 46.8 | 19 | 86.4 | 0.002 |
• Treatment failure | 12 | 25.5 | 2 | 9.1 | 0.198 |
Death within 12 months | 13 | 27.7 | 1 | 4.5 | 0.028 |
• Median time to death (days) | 60 |  | NA |  |  |